$50m · Series B · Healthtech · London, UK
London-based Scarlet has raised a $50m Series B led by Headline to expand its certification platform for software and AI medical devices. Existing investors Kindred Capital, Creandum, Atomico and Entrepreneurs First participated, alongside new investor Notion Capital. Scarlet said the financing will support a larger team of technical and clinical experts, broader certification services and expansion in the US and Asia-Pacific.
Certification becomes part of the software release cycle
Medical-device certification is a gate to market access, but software products can change far more frequently than the processes originally designed to assess them. Scarlet operates as an EU notified body, a UK approved body and an FDA-recognised third-party review organisation. Customers upload technical documentation to its platform, while qualified reviewers make the regulatory judgements. Headline says each finding is tied to source material and specific regulatory clauses, making the assessment traceable for both manufacturers and regulators.
That division of labour is central to Scarlet’s commercial model. Automating document intake and organising evidence can reduce administrative delay, but the certification decision remains with accountable specialists. Scarlet wraps initial assessment, product changes, post-market surveillance and annual audits into an ongoing relationship. For AI-device makers, that could turn certification from a one-off project into infrastructure that supports repeated releases.
The round also funds a capacity problem. Scarlet says demand for AI medical-device certification has risen sharply and claims customers have reduced some certification timelines by a year or more and update cycles from months to weeks. Those are company-reported outcomes rather than independently benchmarked results. Scaling will depend on whether Scarlet can recruit enough qualified reviewers, maintain consistent decisions across jurisdictions and preserve the independence expected of a certification body as its customer base grows.
Regulatory authority is the barrier to entry
Scarlet was founded by James Dewar and Jamie Cox after their work on software medical devices at Babylon Health exposed them to long assessment cycles. The company now counts developers including Skin Analytics, Tandem Health and Flo Health among its customers. Its regulatory designations create a meaningful barrier to entry: prospective competitors need government authorisation and audited quality systems before they can issue certificates.
The financing is ultimately a bet that faster assessment and stricter evidence trails can reinforce each other. If Scarlet can make frequent software updates easier to review without weakening clinical or regulatory scrutiny, certification becomes less of a release bottleneck. The difficult part is proving that the same operating model remains rigorous as the company adds reviewers, certification schemes and markets.
Explore this theme
ImpactVC, hosted on EUVC · 24 August 2025. The article examines the implementation gap in healthcare AI, including the need for iterative regulation and continuous post-deployment oversight.
Sources checked:
Scarlet announcement · Headline investment thesis · Tech.eu Funding Explorer · European Commission NANDO · Tech Funding News
